Laura Joszt, MA

In 90% of patients, psoriasis precedes psoriatic arthritis by an average of 7 years, providing a window of opportunity for early intervention and possible prevention of psoriatic arthritis.

Based on the safety and efficacy outcomes from the PREVENT phase 3 study, the FDA has approved secukinumab (Cosentyx) from Novartis for the treatment of active nonradiographic axial spondyloarthritis.

In the real-world, ruxolitinib's approval to treat myelofibrosis has improved overall survival (OS) for elderly patients.

Measuring disease activity is a key aspect of rheumatologic care, but the creation of tools designed specifically for disease areas of interest has resulted in fragmentation and multiple disease activity scores, sometimes even just for a single disease.

Two abstracts presented at the European Congress of Rheumatology of the European League Against Rheumatism reviewed long-term safety data and real-life effectiveness and safety of secukinumab for ankylosing spondylitis, psoriasis, and psoriatic arthritis.

Patients with psoriasis often have other physical diseases, and these somatic comorbidities can have a bigger effect on the patient’s mental health than the skin symptoms from their psoriasis, according to a study published in JAMA Dermatology.

Recommendations that patients with rheumatoid arthritis see an expert within 6 weeks of symptom onset can provide challenges for practices.

American Medical Group Association (AMGA) is asking CMS to permanently extend the telehealth flexibilities it instituted as a result of the coronavirus disease 2019 (COVID-19).

The incidence of rare cancers is higher in the United States than in Europe, but so is the survival rate, according to a study published in Cancer Medicine.

Drugs used to treat rheumatic conditions suppress the rogue immune system, but it has been unclear whether patients using immunosuppressants have an increased risk of a more severe course if they are infected with the coronavirus disease 2019 (COVID-19).

A global epidemiological study on psoriasis has found that the prevalence, incidence, and burden of suffering caused by the disease has risen over the last 3 decades.

Use of biologics to treat psoriasis may impact prevalence of comorbidities like depression and obesity, according to an abstract presented at the Virtual 2020 International Society for Pharmacoeconomics and Outcomes Research meeting.

For patients with rheumatoid arthritis (RA), cost can play a role in patient adherence to medication, but the presence of comorbidities does not impact cost of care for patients, according to 2 abstracts presented at the Virtual 2020 International Society for Pharmacoeconomics and Outcomes Research meeting.

Discontinuation of ruxolitinib was associated with increased morbidity burden and worse outcomes among patients with myelofibrosis.

Rebecca Kaul, MBA, vice president and chief innovation officer at The University of Texas MD Anderson Cancer Center, said the best technology improves the patient experience.

During a discussion at The American Journal of Managed Care®’s Patient- Centered Oncology Care® meeting in Philadelphia, panelists outlined the efficacy of the 2 FDA-approved therapies, Medicare reimbursement for CAR T-cell therapies, and the pace of innovation in healthcare.

Joshua Ofman, MD, MSHS, gave his keynote address during Patient-Centered Oncology Care, the annual multistakeholder gathering presented by The American Journal of Managed Care® in Philadelphia, Pennsylvania.

Interviews with researchers and opinion leaders that took place during the 61st American Society of Hematology Annual Meeting and Exposition in Orlando, Florida, December 7-10, 2019.

After the United States has moved farther along the path to value-based care, it will need to contend with a host of new challenges and questions regarding how the different pieces of care delivery fit together.

Disease burden is substantial for patients with myelofibrosis, even those with intermediate risk, and a not insubstantial percentage of patients have low or intermediate adherence during treatment, according to 2 abstracts from an Italian clinical trial presented at the 61st American Society of Hematology Annual Meeting & Exposition.

Findings from 2 studies presented at the San Antonio Breast Cancer Symposium highlight the value of genomic profiling for women with breast cancer.

More than 7 months after Scott Gottlieb, MD, resigned from his position as FDA commissioner, the Senate confirmed Stephen Hahn, MD, FASTRO, to be the next head of the agency.

Hereditary transthyretin amyloid cardiomyopathy, which is caused by a genetic variant significantly associated with heart failure in individuals of African descent, is underdiagnosed, according to a new study published in JAMA.

Patients with mantle cell lymphoma (MCL) face a substantial economic burden and susceptibility to adverse events (AEs) in the real world, according to an abstract presented at the 61st American Society of Hematology Annual Meeting and Exposition.

Accountable care organizations (ACOs) have saved Medicare a total of $3.53 billion from 2013 to 2017, or $755 million after shared savings were paid out, according to a new report from the National Association of ACOs (NAACOS).

Historically, patients with severe acute graft-versus-host disease (GVHD) and severe chronic GVHD as determined by the National Institutes of Health have poor survival. New research being presented at the 61st American Society of Hematology Annual Meeting & Exposition shows that earlier treatment with novel therapies can improve outcomes for these patients.

There are no cures available to patients with polycythemia vera (PV), who are first treated with hydroxyurea (HU); ruxolitinib is approved as a second-line therapy in both Europe and the United States for patients who are intolerant of or resistant to HU. Two abstracts being presented at the 61st American Society of Hematology Annual Meeting & Exposition explore the use of ruxolitinib in patients with PV, either in patients who first tried HU or had ruxolitinib as a first-line therapy.

While there is an increased interest in using real-world evidence (RWE) to design, test, and review rare disease treatments, payers may not be as receptive to using RWE when making reimbursement and formulary decisions, according to a new report from Syneos Health.

Researchers may have identified a way to delay the progression of multiple sclerosis (MS) by blocking a molecule that controls the entry of B cells into the brain, which results in deterioration of tissue.

The FDA has approved a new treatment for adult patients with acute hepatic porphyria (AHP) a rare genetic disorder. Givlaari is an RNA interference therapeutic targeting aminolevulinic acid synthase 1. Simultaneously, Alnylam Pharmaceuticals announced a new framework for value-based agreements to help patients gain access to the treatment.